{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:37:11Z","timestamp":1774489031725,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972864"],"award-info":[{"award-number":["81972864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Academic Promotion Program of Shandong First Medical University","award":["2019RC002"],"award-info":[{"award-number":["2019RC002"]}]},{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation Teams of Universities in Shandong Province","doi-asserted-by":"crossref","award":["2019KJL001"],"award-info":[{"award-number":["2019KJL001"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Plan of Jinan","award":["201907113"],"award-info":[{"award-number":["201907113"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2020LZL018"],"award-info":[{"award-number":["ZR2020LZL018"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["No. tsqn202103174"],"award-info":[{"award-number":["No. tsqn202103174"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00432-021-03848-4","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T05:03:45Z","timestamp":1636347825000},"page":"2661-2671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer"],"prefix":"10.1007","volume":"148","author":[{"given":"Xuetian","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuihua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-6228","authenticated-orcid":false,"given":"Jisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"3848_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2015.10.016","volume":"54","author":"F Abdelraouf","year":"2016","unstructured":"Abdelraouf F, Smit E, Hasan B, Menis J, Popat S, Van Meerbeeck JP, Surmont VF, Baas P, O\u2019Brien M (2016) Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a \u2018chemosensitive\u2019 relapse: a single-arm phase ii study (EORTC-08061). Eur J Cancer 54:35\u201339. https:\/\/doi.org\/10.1016\/j.ejca.2015.10.016","journal-title":"Eur J Cancer"},{"issue":"4","key":"3848_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.bbamcr.2012.01.004","volume":"1823","author":"I Ahmad","year":"2012","unstructured":"Ahmad I, Iwata T, Leung HY (2012) Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta-Mol Cell Res 1823(4):850\u2013860. https:\/\/doi.org\/10.1016\/j.bbamcr.2012.01.004","journal-title":"Biochim Biophys Acta-Mol Cell Res"},{"issue":"10","key":"3848_CR3","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276\u20131312. https:\/\/doi.org\/10.1101\/gad.1653708","journal-title":"Genes Dev"},{"issue":"7","key":"3848_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","volume":"17","author":"SJ Antonia","year":"2016","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, J\u00e4ger D et al (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol 17(7):883\u2013895. https:\/\/doi.org\/10.1016\/S1470-2045(16)30098-5","journal-title":"Lancet Oncol"},{"issue":"9","key":"3848_CR5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","volume":"21","author":"N Baize","year":"2020","unstructured":"Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A et al (2020) Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 21(9):1224\u20131233. https:\/\/doi.org\/10.1016\/S1470-2045(20)30461-7","journal-title":"Lancet Oncol"},{"issue":"10","key":"3848_CR6","doi-asserted-by":"publisher","first-page":"S351","DOI":"10.1016\/j.jtho.2018.08.308","volume":"13","author":"Y Cheng","year":"2018","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Wu L, Han B, Chen G et al (2018) OA13.03 anlotinib as third-line or further-line treatment in relapsed sclc: a multicentre, randomized, double-blind phase 2 trial. J Thorac Oncol 13(10):S351\u2013S352. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.308","journal-title":"J Thorac Oncol"},{"issue":"10","key":"3848_CR7","doi-asserted-by":"publisher","first-page":"S823","DOI":"10.1016\/j.jtho.2019.08.1771","volume":"14","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Han B, Wu L, Chen G et al (2019a) P2.12-26 the impact of anlotinib for relapsed SCLC patients with brain metastases: a subgroup analysis of ALTER 1202. J Thorac Oncol 14(10):S823\u2013S824. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.1771","journal-title":"J Thorac Oncol"},{"key":"3848_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz264.002","volume":"30","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B et al (2019b) Overall survival (OS) update in ALTER 1202: anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Ann Oncol 30:v711. https:\/\/doi.org\/10.1093\/annonc\/mdz264.002","journal-title":"Ann Oncol"},{"issue":"4","key":"3848_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, Delord JP et al (2020) Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol 15(4):618\u2013627. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.109","journal-title":"J Thorac Oncol"},{"issue":"6","key":"3848_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and Its receptors. Nat Med 9(6):669\u2013676. https:\/\/doi.org\/10.1038\/nm0603-669","journal-title":"Nat Med"},{"key":"3848_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2016.04.002","volume":"96","author":"JY Han","year":"2016","unstructured":"Han JY, Kim HY, Lim KY, Hwangbo B, Lee JS (2016) A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer 96:108\u2013112. https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.002","journal-title":"Lung Cancer"},{"issue":"11","key":"3848_CR12","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang Li, Shi J, Wang Z, Cheng Y et al (2018) Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 4(11):1569\u20131575. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039","journal-title":"JAMA Oncol"},{"issue":"5","key":"3848_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"2","key":"3848_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/annonc\/mdy551","volume":"30","author":"KM Heinhuis","year":"2019","unstructured":"Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM (2019) Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 30(2):219\u2013235. https:\/\/doi.org\/10.1093\/annonc\/mdy551","journal-title":"Ann Oncol"},{"issue":"5","key":"3848_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011\u20131027. https:\/\/doi.org\/10.1200\/JCO.2005.06.081","journal-title":"J Clin Oncol"},{"issue":"5","key":"3848_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41571-019-0316-z","volume":"17","author":"WT Iams","year":"2020","unstructured":"Iams WT, Porter J, Horn L (2020) Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol 17(5):300\u2013312. https:\/\/doi.org\/10.1038\/s41571-019-0316-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"15_suppl","key":"3848_CR17","doi-asserted-by":"publisher","first-page":"8560","DOI":"10.1200\/JCO.2021.39.15_suppl.8560","volume":"39","author":"T Kong","year":"2021","unstructured":"Kong T, Chen L, Duan F, Hou X, Wang L, Zhou H, Wang L, Hu S, Liu D (2021) Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin\/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): the final results from a phase II single-arm trial. J Clin Oncol 39(15_suppl):8560\u20138560. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8560","journal-title":"J Clin Oncol"},{"key":"3848_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","volume":"654","author":"B Lin","year":"2018","unstructured":"Lin B, Song X, Yang D, Bai D, Yao Y, Na Lu (2018) Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFR\u03b2 and FGFR1. Gene 654:77\u201386. https:\/\/doi.org\/10.1016\/j.gene.2018.02.026","journal-title":"Gene"},{"issue":"6","key":"3848_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S1010-7940(02)00112-4","volume":"21","author":"M Lucchi","year":"2002","unstructured":"Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti CA (2002) Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 21(6):1105\u20131110. https:\/\/doi.org\/10.1016\/S1010-7940(02)00112-4","journal-title":"Eur J Cardiothorac Surg"},{"issue":"34","key":"3848_CR20","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/jco.2017.72.5069","volume":"35","author":"PA Ott","year":"2017","unstructured":"Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM (2017) Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol 35(34):3823\u20133829. https:\/\/doi.org\/10.1200\/jco.2017.72.5069","journal-title":"J Clin Oncol"},{"issue":"12","key":"3848_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.20.02212","volume":"39","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR et al (2021) Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol: off J Am Soc Clin Oncol 39(12):1349\u20131359. https:\/\/doi.org\/10.1200\/JCO.20.02212","journal-title":"J Clin Oncol: off J Am Soc Clin Oncol"},{"issue":"10212","key":"3848_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"3848_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.04.009","volume":"144","author":"S Popat","year":"2020","unstructured":"Popat S, Groh\u00e9 C, Corral J, Reck M, Novello S, Gottfried M, Radonjic D, Kaiser R (2020) Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: do they have a role in non-oncogene-addicted non-small cell lung cancer? Lung Cancer 144:76\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.009","journal-title":"Lung Cancer"},{"issue":"2","key":"3848_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","volume":"20","author":"RR Ramjiawan","year":"2017","unstructured":"Ramjiawan RR, Griffioen AW, Duda DG (2017) Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis 20(2):185\u2013204. https:\/\/doi.org\/10.1007\/s10456-017-9552-y","journal-title":"Angiogenesis"},{"issue":"2","key":"3848_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR et al (2019) Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 14(2):237\u2013244. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.003","journal-title":"J Thorac Oncol"},{"issue":"21","key":"3848_CR26","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, Cheema PK et al (2020) Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 Study. J Clin Oncol 38(21):2369\u20132379. https:\/\/doi.org\/10.1200\/JCO.20.00793","journal-title":"J Clin Oncol"},{"issue":"3","key":"3848_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2174\/1389450117666160502152331","volume":"18","author":"G Russo","year":"2017","unstructured":"Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C et al (2017) Small-cell lung cancer: clinical management and unmet needs new perspectives for an old problem. Curr Drug Targets 18(3):341\u2013362. https:\/\/doi.org\/10.2174\/1389450117666160502152331","journal-title":"Curr Drug Targets"},{"issue":"2","key":"3848_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccm.2020.02.011","volume":"41","author":"A Saltos","year":"2020","unstructured":"Saltos A, Antonia S (2020) Breaking the impasse: advances in treatment of small cell lung cancer. Clin Chest Med 41(2):269\u2013280. https:\/\/doi.org\/10.1016\/j.ccm.2020.02.011","journal-title":"Clin Chest Med"},{"issue":"1","key":"3848_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Feng Du, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development 11 medical and health sciences 1112 oncology and carcinogenesis. J Hematol Oncol 11(1):1\u201311. https:\/\/doi.org\/10.1186\/s13045-018-0664-7","journal-title":"J Hematol Oncol"},{"issue":"13","key":"3848_CR30","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1002\/cam4.2462","volume":"8","author":"X Shi","year":"2019","unstructured":"Shi X, Dong X, Young S, Chen AM, Liu X, Zheng Z, Huang K et al (2019) The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer. Cancer Med 8(13):5930\u20135938. https:\/\/doi.org\/10.1002\/cam4.2462","journal-title":"Cancer Med"},{"key":"3848_CR31","volume-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Annals of oncology","author":"DR Spigel","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C et al (2021) Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Annals of oncology, vol 32. European Society for Medical Oncology"},{"issue":"4","key":"3848_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.21037\/tlcr.2016.08.04","volume":"5","author":"M Stratigos","year":"2016","unstructured":"Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V (2016) Targeting angiogenesis in small cell lung cancer. Transl Lung Cancer Res 5(4):389\u2013400. https:\/\/doi.org\/10.21037\/tlcr.2016.08.04","journal-title":"Transl Lung Cancer Res"},{"issue":"May","key":"3848_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2020.00741","volume":"10","author":"H Taniguchi","year":"2020","unstructured":"Taniguchi H, Sen T, Rudin CM (2020) Targeted therapies and biomarkers in small cell lung cancer. Front Oncol 10(May):1\u20137. https:\/\/doi.org\/10.3389\/fonc.2020.00741","journal-title":"Front Oncol"},{"key":"3848_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","volume":"893","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1\u201319. https:\/\/doi.org\/10.1007\/978-3-319-24223-1_1","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"3848_CR35","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/1759-7714.13120","volume":"10","author":"Di Wu","year":"2019","unstructured":"Wu Di, Nie J, Dai L, Weiheng Hu, Zhang J, Chen X, Ma X et al (2019) Salvage treatment with anlotinib for advanced non-small cell lung cancer. Thoracic Cancer 10(7):1590\u20131596. https:\/\/doi.org\/10.1111\/1759-7714.13120","journal-title":"Thoracic Cancer"},{"issue":"4","key":"3848_CR36","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Li Fu, Li Y, Lou L (2018) Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 109(4):1207\u20131219. https:\/\/doi.org\/10.1111\/cas.13536","journal-title":"Cancer Sci"},{"issue":"9","key":"3848_CR37","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/JTO.0b013e3181a97e31","volume":"4","author":"P Zhan","year":"2009","unstructured":"Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Li Ke Yu, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094\u20131103. https:\/\/doi.org\/10.1097\/JTO.0b013e3181a97e31","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03848-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03848-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T08:12:52Z","timestamp":1663056772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03848-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["3848"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03848-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No authors report any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of Shandong Cancer Hospital (Shandong Province, China) approved this study. In this retrospective study, the privacy and personal information of all patients were protected, and all the procedure was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}